文献速递主动脉疾病

新型升主动脉内移植物用于升主动脉与主动脉弓病变的紧急与同情使用

Emergency and Compassionate Use of a Novel Ascending Endograft for Ascending and Arch Aortic Pathology.
PubMed 文献 · J Endovasc Ther · 2023-11-07

本病例系列评估19例(平均年龄68.84±13.12岁,女性57.9%)复杂升主动脉病变患者紧急或同情使用新型升主动脉内移植物行胸主动脉腔内修复的早期结果;器械输送全部成功(100%),30天死亡3例(15.8%)、卒中1例(5.3%),内漏6例(31.6%)。

要点

  • 19例复杂升主动脉病变患者紧急或同情使用新型升主动脉内移植物,器械输送成功率100%。
  • 30天死亡3例(15.8%),卒中1例(5.3%),内漏6例(31.6%)。
  • 作者认为该新型器械在复杂解剖与病变中可行,更多经验将进一步明确最适合腔内修复的人群。

核心结论

  • 新型升主动脉胸主动脉覆膜支架伴或不伴附加分支弓部延伸,在复杂解剖与病变(包括急性主动脉夹层和假性动脉瘤)患者中输送与释放可行。
  • 作者认为更多该新型器械的经验将进一步明确最适合腔内升主动脉修复这些病变的人群。

研究设计与样本

  • 病例系列,评估19例(平均年龄68.84±13.12岁,女性57.9%)因急性及慢性主动脉夹层或假性动脉瘤接受升主动脉胸主动脉腔内修复的患者。
  • 19例中6例(31.5%)为同情使用,13例(68.4%)为紧急使用豁免;10例(52.6%)接受附加器械以延伸至弓部和降主动脉。

主要发现

  • 所有患者均实现器械输送(100%)。
  • 30天死亡3例(15.8%),卒中1例(5.3%)。
  • 1例(5.3%)发生非预期器械不良事件,覆膜支架侵蚀至升主动脉壁后壁夹层部位外膜时主动脉破裂。
  • 2例(10.5%)分别在指数手术后353天和610天取出器械。
  • 6例发生内漏(31.6%),包括I型(n=2,10.5%)、II型(n=3,15.8%)和不确定型内漏(n=1,5.3%)。

临床怎么用

  • 原文结论未据此给出推荐。

局限性

  • 原文未报告局限性。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

PURPOSE: Patients with complicated ascending aortic pathology, including patients with acute type A aortic dissection may be at extreme risk for open repair. Thoracic endovascular aortic repair (TEVAR), infrequently used for the ascending aorta, may be considered an alternative in this setting. We describe early results for emergency and compassionate (E&C) use of a novel endograft, specifically designed for use to treat pathology of the ascending aorta. MATERIALS AND METHODS: This case series evaluated 19 patients (mean age, 68.84±13.12 years; 57.9% female) treated with ascending TEVAR for acute and chronic acute (4), subacute (1), or chronic (1) aortic dissection or pseudoaneurysm (13). Six of the 19 patients (31.5%) were treated under compassionate use and 13 patients (68.4%) were treated under the emergency use exemption. Ten patients (52.6%) received additional devices to extend treatment into the arch and descending aorta. RESULTS: Device delivery was achieved in all patients (100%). Thirty-day mortality and stroke occurred in 3 patients (15.8%) and in 1 patient (5.3%), respectively. In 1 patient (5.3%), with an Unanticipated Adverse Device Event, the aorta ruptured when the endograft eroded into the adventitial portion of dissection site at the posterior aspect of the ascending wall. Devices were explanted in 2 patients (10.5%), 353 and 610 days after the index procedure, respectively. Six patients had endoleaks (31.6%), including type I (n=2, 10.5%), type II endoleaks (n=3, 15.8%), and indeterminate endoleak (n=1, 5.3%). CONCLUSIONS: Delivery and deployment of a novel ascending thoracic stent graft with or without an additional branched arch extension is feasible in patients with complex anatomy and pathology, including acute aortic dissection and pseudoaneurysm. Additional experience with this novel device will further refine the patient population most suitable for endovascular ascending aortic repair for these pathologies.Clinical ImpactThis study describes a novel stent graft specifically designed for treatment of ascending aortic pathology, including acute type A dissection. The patients described in this series constituted a group outside the formal US FDA sponsored clinical trial, and were those accepted as part of an emergency and compassionate use basis.

来源:J Endovasc Ther,查看原文。版权归原作者所有。

引用

  1. Patel HJ, Preventza O, Roselli EE, et al. Emergency and Compassionate Use of a Novel Ascending Endograft for Ascending and Arch Aortic Pathology. J Endovasc Ther. 2023. PMID: 37933168. doi:10.1177/15266028231208644

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。